Abstract Ankylosing spondylitis is an inflammatory disorder affecting the axial skeleton and periphery. Symptoms can often be debilitating. Current therapy for the disease include physical therapy, non-steroidal anti-inflammatory drugs (NSAIDS, anti-rheumatic disease modifying drugs (DMAR-DS), and the newly developed biologic agents targeting tumor necrosis factor alpha (TNF-α). This paper will provide a comprehensive review of these treatments which focusing on evidence based medicine for the daily clinical practice of rheumatology.
Introduction
Ankylosing spondylitis (AS) is a chronic inflammatory disease of the axial skeleton with variable involvement of peripheral joints and non-articular structures. It is the most common among a group of diseases known as the seronegative spondyloarthropathies. While disease manifestations and the rate of progression are variable, untreated AS may produce significant morbidity and increased mortality [1, 2] . A comparison of AS with rheumatoid arthritis (RA) demonstrates a comparable degree of severe disability between the two diseases, increasing as a function of both patient age and duration of disease [3] . Furthermore, the reported prevalence of severe pain in AS is as high as 44.6%. The extra-articular manifestations of AS that contribute to disease-associated morbidity include enthesopathy, anterior uveitis, aortitis and heart block, and fibrocystic pulmonary disease.
Over the last 30 years, the treatment of AS has evolved from symptomatic relief to modification of disease activity and the associated morbidity and mortality. No single agent has been demonstrated to treat all manifestations of AS, and thus combination therapy is required to relieve symptoms, stabilize or improve function, and slow or halt disease progression in most patients.
Non-steroidal anti-inflammatory drugs
Pain is a significant and persistent component of AS. The pain classically begins as inflammatory low back pain, but may involve any area of the spine. This pain is often worse in the morning and improves with exercise, as opposed to mechanical back pain that worsens with movement and improves with rest. Over time, progressive ankylosis of the spine produces fixed deformities, with decreased range of motion and muscle spasm. Peripheral involvement is typically an oligoar-ticular asymmetric synovitis of the lower extremities and enthesitis. Non-steroidal anti-inflammatory drugs (NSAIDs) have been shown to be effective in relief of both axial and peripheral symptoms and enthesitis. Indomethacin is most commonly utilized, but efficacy and safety are comparable between most of the non-selective NSAIDs. A randomized trial of the COX-2-selective agent celecoxib showed similar efficacy to the non-selective agent ketoprofen, and superiority to placebo in both global and spinal pain measurements. In addition, both agents were reported to improve global function [Bath Ankylosing Spondylitis Functional Index (BASFI)], patient overall assessment [visual analog scale (VAS)], spinal range of motion (modified Schober's test), and sleep disturbance compared with placebo [4] . Similar efficacy may be anticipated with other COX-2-selective agents. Clinical experience has shown significant variability within an individual patient to the different NSAIDs. It is therefore considered appropriate to utilize adequate doses of at least two different NSAIDs, preferably from different classes, over a minimum 6 weeks prior to concluding a patient has had an inadequate response.
Despite the proven benefits of NSAIDs, utilization of both classes (non-selective and COX-2) is limited by low response rates and significant side effects. Approximately 50% of patients with AS obtained insufficient pain relief from NSAIDs, while over 60% experienced an adverse reaction to both classes [4] . In addition, while the clinical trials have been of short duration, no evidence exists that NSAIDs affect the frequency, severity, or progression of the articular and extra-articular manifestations of AS. The high frequency of adverse effects and a lack of efficacy in limiting disease progression may require that other agents be used in conjunction with NSAIDs.
Physical therapy and muscle relaxants
Decreased range of motion at both axial and peripheral joints and progressive kyphosis of the spine are significant contributors to disease-specific morbidity. This impaired mobility is due to a combination of pain, ankylosis, and muscle spasm. Appropriate regular exercise is extremely important for patients with spondylitis to maintain function and posture. Physical therapy or hydrotherapy with an emphasis on posture, range of motion, and strengthening is also helpful. Patients with a significant degree of muscle spasm may respond to a combination of analgesics and muscle relaxants.
Corticosteroids
Corticosteroids exert significant anti-inflammatory and immunosuppressive effects and have demonstrated some 160 efficacy in the treatment of AS. Both axial and peripheral joint pain and swelling respond to corticosteroids.
Oral corticosteroids have not been formally studied in a placebo-controlled fashion, however low-dose therapy may be efficacious in decreasing symptoms. Prolonged treatment courses with oral corticosteroids are contraindicated, based on disease-specific side effects and a lack of efficacy in slowing disease progression. AS is associated with accelerated spinal osteoporosis through a combination of elevated inflammatory cytokines and ankylosis-associated immobility [5] [6] [7] . Oral steroids may accelerate osteoporosis and contribute to the early development of painful vertebral compression fractures without decreasing the rate of disease.
Pulsed intravenous methylprednisolone therapy, 375-1,000 mg daily for 3 days, was reported in uncontrolled trials to produce improvement in morning stiffness, back pain, and spinal mobility [8, 9] . A comparison between 375-and 1,000-mg doses showed no significant differences in response. While symptom reduction was observed in some individuals at up to 21 months after infusion, the majority of low-and high-dose patients resumed analgesics and antiinflammatory medications after only 8 and 25 days, respectively [8] . In addition, pulsed steroids have not been demonstrated to slow disease progression and this form of therapy has potential for significant adverse side effects.
Local corticosteroid injections of joints and entheses can provide temporary relief of symptoms. Injections are preferable to systemic steroids for treatment of monoarticular flairs or the localized enthesitis of AS. Fluoroscopic or computed tomography guided corticosteroid injections of the sacroiliac joints was shown to provide symptomatic relief in a double-blind study [10] .
Most agree that anterior uveitis is the one extra-articular manifestation of AS that responds most effectively to corticosteroids. Urgent evaluation and treatment of uveitis with a combination of topical corticosteroid drops and mydriatic agents, such as topical atropine, is critical for preservation of vision and prevention of synechia formation.
Tricyclic antidepressants
AS has been shown to be associated with sleep disturbance and fatigue in several studies [11] [12] [13] . Fatigue was considered a major symptom of AS by 65% of patients, while 41% reported concomitant sleep disturbance [11] . The use of lowdose amitriptyline (30 mg/day) was shown to improve sleep and decrease the disease activity index [Bath Ankylosing Spondylitis Disease Activity Index (BASDAI)] over a 2-week trial period [14] . Whether this benefit persists over a longer period has yet to be determined. Amitriptyline was generally well tolerated, with minimal discontinuation of the drug secondary to side effects.
Pamidromate
Pamidromate is an intravenously administered member of the bisphosphonate family, a class of drugs used to inhibit bone resorption. The rationale for the use of pamidromate in inflammatory arthritis evolved from a series of studies demonstrating the wide-ranging effects of bisphosphonates on bone metabolism, inflammation, and immune regulation. Bisphosphonates inhibit osteoclast function, promote osteoclast apoptosis [15] , inhibit cytokine production [16] , and inhibit antigen presentation on peripheral blood monocytes [17] . In both open-label [18] and blinded studies [19] , monthly infusion of pamidromate (60 mg) was shown to decrease disease activity (BASDAI 34.5% vs. placebo 15%, P=0.002). Pamidromate also produced improvement in the functional, global, and metrology indexes. Most clinically significant were changes in disease activity, with 63.4% of the pamidromate group obtaining ≥25% improvement in disease activity compared with 30.2% in the placebo group. The most-common side effects of therapy were dose-dependent arthralgias and myalgias, most often following the first infusion (68.3% of the 60-mg group) [19] . A transient lymphopenia lasting 7-10 days was also observed in a small number of patients.
Thalidomide
Thalidomide is a glutamic acid derivative that produces antiinflammatory and immunomodulatory effects [20] . In vitro, thalidomide can reduce production of tumor necrosis factor (TNF) by almost 40%. This inhibition occurs at the transcriptional level through reduction in the half-life of TNF mRNA [20] . Thalidomide has also been demonstrated to inhibit chemotactic and phagocytic pathways. Despite this immunomodulatory role, thalidomide does not exert significant immunosuppression and its use is not associated with opportunistic infection.
The first reported use of thalidomide for spondylitis was published in 1999 [21] . This open-label trial involving two patients reported a reduction in clinical (axial and peripheral synovitis) and biological markers of inflammation [(erthrocyte sedimentation rate (ESR) and C-reactive protein (CRP)].
Two open-label follow-up studies reported a total of 43 patients, 13 of whom were considered to have refractory AS [22] . In a 12-month study of 30 patients [22] , 80% showed a significant response (>20%) in four of seven indices, while nearly 50% had a ≥50% improvement. Secondary outcomes, including reductions in ESR and CRP, were also observed. Maximum beneficial effects of thalidomide were observed following 6-12 months of therapy and significant clinical relapse occurred 3 months after discontinuation of the drug.
In a 6-month study of 13 patients characterized as having severe, refractory AS, 10 patients completed the study. Of these 10 patients, 4 achieved a 50% improvement and 4 achieved a 20% improvement in the Assessments In Ankylosing Spondylitis Working Group (ASAS) criteria. Statistically significant improvement was achieved for BAS-DAI, BASFI, Bath Ankylosing Spondylitis Global (BAS-G), and ESR. Three patients in this study withdrew due to treatment side effects (skin rash), 2 withdrew due to lack of efficacy, and 2 who completed the study failed to achieve significant improvement.
The tolerability and side effects of thalidomide vary significantly between studies. This may actually represent differences in dosing regimens utilized in different studies. Commonly reported side effects included drowsiness, constipation, dizziness, headache, nausea/vomiting, and paresthesias. No serious side effects such as phocomelia have been reported.
Sulfasalazine
Sulfasalazine (SSZ) is a salicyclic acid derivative created by covalent linkage of mesalamine (5-amino-salicyclic acid) to sulfapyridine. The drug is activated by colonic bacteria through cleavage of the covalent bond. Mesalamine absorption is limited to the colonic wall, where the drug has demonstrated activity against inflammatory bowel disease. The sulfapyridine moiety is well absorbed and, following hepatic acetylation, acts systemically to produce disease-modifying effects [23] . Following successful trials of SSZ in both RA and inflammatory bowel disease, numerous trials to assess efficacy in AS have been undertaken.
A meta-analysis of five randomized controlled trials involving a total of 272 patients was published in 1990 [24] . Most studies used SSZ in doses between 2 and 3 g/day. Benefit was demonstrated in three clinical and four laboratory parameters. SSZ decreased the severity and duration of morning stiffness (30.6% and 28.2%, respectively) and the severity of pain (26.7%) over trial periods ranging from 3 to 11 months. Immunoglobulin levels (IgM, IgG, IgA) decreased in the treatment group. General well-being, ESR, CRP, and spinal mobility measurements showed non-significant trends in favor of SSZ. Only one of the five trials in this meta-analysis evaluated response rates in axial versus peripheral symptoms, with a non-statistically significant trend favoring response of peripheral symptoms [25] .
In a follow-up study, 351 patients with spondyloarthropathy were enrolled in a double-blind placebo-controlled trial of SSZ [26] . The patients were categorized into three subsets, AS, psoriatic arthritis, and reactive arthritis. In an intention-to-treat analysis, SSZ showed statistically significant improvement in only one of four primary outcomes, the patient global assessment (P=0.007). In a subgroup analysis of those completing the study, benefit of SSZ was seen in three of four treatment outcomes, including visual analog pain scale (VAS pain, P=0.03), patient overall assessment (P=0.006), and physician overall assessment (P=0.031). The beneficial effects of SSZ were limited to patients with peripheral arthritis, and there was a trend towards improved response rate in patients with early disease [26, 27] . The radiographic and clinical measurements of disease progression were unaffected by the addition of SSZ to the treatment regimen. In the above trial, a total of 33 of 179 SSZ-treated patients withdrew from the study, either due to lack of efficacy (5) or treatment side effects [27] . Adverse events occurred in 108 patients in the SSZ group (60%) versus 83 patients in the placebo group (48%) (P=0.023). All adverse events were reversible following discontinuation of therapy. Nausea was the most frequently reported adverse event occurring, in 20% of SSZ group versus 7.5% of the placebo group.
In a double-blind placebo-controlled trial of 60 patients with arthritis limited to the axial skeleton, treatment with SSZ 2 g/day produced statistically significant reduction in eight clinical and laboratory disease parameters [28] . The treatment group had a reduction in NSAID use, pain, joint index, functional index, hand-ground distance, as well as ESR, IgG, and IgM. The patient population in this study is notable for inclusion of 8 patients with either limited psoriasis or a family history of psoriasis and the failure to rigorously exclude inflammatory bowel disease as the etiology of the arthritis.
The effect of SSZ on the extra-articular manifestations of AS is not well documented, possibly reflecting the small number of patients evaluated and the relatively short duration of current trials. In a 6-month trial by Dougados et al. [26] of 351 patients, 1 of 179 SSZ-treated patients and 6 of 172 placebo-treated patients reported a least one attack of anterior uveitis. A single blinded study showed potential benefit of SSZ in reducing acute anterior uveitis [29] .
Methotrexate
Prospective studies of methotrexate (MTX) have shown little benefit in the treatment of AS, despite proven long-term efficacy and tolerability in RA. The disease-modifying characteristics of MTX, a folate analogue, are derived from disruption of several enzymatic pathways. Direct inhibition of dihydrofolate reductase by MTX leads to impairment of DNA synthesis and lymphocyte proliferation. A polyglutamated form of MTX enhances adenosine release, resulting in down-regulation of the inflammatory pathway via adenosine receptors on peripheral blood monocytes [30] . In an open study of MTX (7.5-15 mg once a week), 11 patients who had previously demonstrated an inadequate response to either NSAIDs or SSZ were evaluated over 36 weeks. This study 162 indicated a potential for MTX to reduce the number of swollen joints in patients with a predominance of peripheral arthritis [31] . The 2 patients in this study with significant extra-articular disease (both with enthesitis and iridocyclitis) discontinued MTX due to persistence of symptoms or progression of disease. A randomized, placebo-controlled trial of MTX in AS failed to demonstrate significant benefit in either axial or peripheral arthritis [32] . The majority of patients in this study had long-standing disease (≥10 years). Two patients with relatively short duration of disease had some symptomatic relief with MTX and chose to continue the drug beyond the 24-week study period. As with other studies of MTX, the drug was generally well tolerated, with no irreversible side effects following discontinuation of the medicine.
Biological agents
The failure of conventional therapies to control symptoms in a significant portion of AS patients and the lack of evidence demonstrating that these therapies inhibit progression of axial disease necessitates improved therapy. Extensive rationale exists for the use of TNF-α inhibition in AS, and a growing body of evidence demonstrates the clinical efficacy of this approach.
Pathophysiologically, TNF-α appears to play a role in promoting the inflammatory pattern associated with AS. Increased TNF-α protein is found in the sacroiliac joints [33] and peripheral synovium [34, 35] , as well as the serum [36, 37] of patients with active AS. While disease activity cannot be predicted from levels of TNF-α, blockade of this protein has increasingly been shown to have benefits in animal models and human studies of AS.
Currently there are two licensed TNF-α inhibitors, infliximab, a chimeric human/mouse IgG1 monoclonal antibody, and etanercept, a divalent soluble TNF-α receptor p75 IgG1 Fc fusion protein.
Infliximab
Early case reports and short-term open-label trials of infliximab demonstrated that TNF-α blockade produced a rapid reduction in the symptoms of AS. In an open-label trial of 11 patients who had discontinued corticosteroid and diseasemodifying anti-rheumatic drug (DMARD) therapy, 9 patients obtained a 70% median reduction in the disease activity index (BASDAI) [38] . These patients received a total of three infusions (5 mg/kg) at weeks 0, 2, and 6 (standardized loading schedule). Remarkably, onset of benefit was noted within 24 h of the first infusion in some patients and the benefit persisted for 6 weeks after the last infusion.
Spinal and peripheral symptoms, fatigue, and morning stiffness all improved during the trial. Infliximab was generally well tolerated, with only 1 patient withdrawing due to urticaria. Three additional open-label trials involving more than 60 AS patients and over 1 year of follow-up demonstrated disease activity reductions of up to 93% [39] [40] [41] . Impressively, the benefits were seen in patients who had failed all previous therapies and, for the first time, a significant reduction in axial skeletal symptoms was demonstrated.
Open-label studies have also shown a reduction in biological and radiographic abnormalities in active AS patients treated with infliximab. A study of eight patients with spondylitis found infliximab decreased acute-phase reactants, decreased synovial vascularity, and decreased synovial inflammatory cell infiltration [42] . Magnetic resonance imaging (MRI) data in this study demonstrated improvement of inflammatory signals at sites of musculoskeletal involvement as well. Early data indicate this reduction in bone inflammation correlates with a reduction in bony progression of AS and a number of studies are ongoing to further evaluate this possibility.
Randomized, placebo-controlled trials of infliximab have supported the earlier results of open-label trials. A 12-week trial of 70 patients with severe AS, defined as a disease activity score ≥4, demonstrated improvement in the treatment group across a wide range of clinical and biological measurements [43] . Patients enrolled in this trial were permitted to continue a stable dose of NSAIDs, but must have discontinued DMARDs and steroids 4 weeks prior to enrollment. The treatment group received infliximab dosed at 5 mg/kg over the standardized loading schedule; 53% of the treatment group obtained the primary outcome, a 50% reduction in disease activity, compared with only 9% in the placebo group (P<0.0001). The treatment group had a statistically significant reduction in fatigue, spinal pain, peripheral joint arthritis, enthesitis, and morning stiffness compared with placebo. Biological markers (ESR and CRP) decreased in the treatment group, but not in the placebo group (P<0.0001). Four patients in the treatment group discontinued therapy, 1 due to lack of efficacy and 3 due to significant side effects. One patient developed disseminated tuberculosis (the patient had not undergone PPD testing or pre-treatment chest X-ray). A second patient developed bronchiocentric allergic granulomatosis that resolved with discontinuation of therapy. The last patient developed transient leukopenia (white blood cell count = 2.6x10 9 /l) that also resolved. In an open-label extension with cross-over of the placebo group, a similar 49% of patients achieved a 50% reduction in disease activity. This response was sustained for the duration of the 54-week follow-up. While this study was not powered to detect differences in extra-articular manifestations of AS, approximately 50% of the patients had a history of acute anterior uveitis. During the study, acute anterior uveitis developed in 1 patient in the treatment group and 3 patients in the placebo group. The single episode of uveitis in the treatment group occurred in a patient who failed to obtain a BASDAI response of 20%, and was therefore classified as a nonresponder.
A second randomized, placebo-controlled trial of 40 patients with spondyloarthritis, including 19 patients with AS, showed similar improvement during a 12-week treatment period [44] . Patients were permitted to continue stable doses of NSAIDs and corticosteroids prior to receiving a standard 5 mg/kg of infliximab loading schedule. Improvement of greater than 50 mm on a 100-mm VAS was observed in the two primary outcomes, the patient and doctor global assessments (P<0.001 for both). The disease activity index and peripheral synovitis also improved. All improvements were maintained over the duration of the 1-year open-label extension.
Etanercept
The efficacy of etanercept in AS was demonstrated in a double-blind placebo-controlled trial of 40 patients with active spondylitis [45] . Patients in the trial all had spinal pain and stiffness despite stable doses of NSAIDs, low-dose prednisone, and stable doses of other DMARDs. Patients randomized to the etanercept group demonstrated a rapid and sustained response in four primary outcome measures, duration of morning stiffness, nocturnal pain, patient global assessment, and functional index (BASFI). The mean swollen joint count did not differ between the treatment and placebo groups, although this result has been reported by other authors [46] . A number of secondary outcomes also improved, including spinal and chest range of motion, enthesitis, and ESR and CRP levels. During the open-label, crossover, 6-month extension of this study, initiation of etanercept in the placebo group produced a similar early benefit, which was sustained for both groups over the duration of the 10-month trial. Minimal adverse events were recorded, with no withdrawals from the active treatment group attributable to etanercept. The most-frequent side effects were injection-site reactions and minor infections, which did not differ statistically between the two groups.
A 6-week placebo-controlled trial of 30 AS patients demonstrated a 57% decrease in disease activity (BASDAI) compared with just 6% in the control group (P=0.004) [38] . The treatment group had significant improvement in function (BASFI) and CRP. There was a non-significant trend towards a decrease in number of swollen joints and enteritis. Symptom relapse occurred at a mean time of 3 weeks following discontinuation of etanercept.
Radiographic evidence of the benefit of etanercept was published in an uncontrolled study of ten patients with active spondylitis [46] . Serial MRI demonstrated 86% of bone lesions improved or resolved (6 of 15 sacroiliac lesions and 17 of 22 spinal lesions) in patients treated for a period of 24 weeks. During this same period, no new bone lesions appeared. Radiographic improvement corresponded to improvement in function (BASFI), disease activity index (BASDAI), spinal pain, and Quality of Life scores. Radiographic progression in patients with erosive psoriatic arthritis, treated with etanercept, has recently been published [47] ; 205 patients with psoriatic arthritis, treated with etanercept for 1 year, were evaluated by radiologists blinded to both the treatment and chronological order of the images. Using a modified Sharp method [48], a significant difference was found in the mean rate of radiographic changes. The etanercept group had a mean change in Sharp score of -0.2, while the placebo group mean change was +1.03 (P<0.0001). Significant differences were also found in mean rate of erosion and joint space narrowing (P<0.0001 and P=0.04). As with infliximab, studies are ongoing to assess the correlation between bone inflammation as detected by MRI and the rate of radiographic progression of the bony lesions of AS. 
